On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was 7.72% up from the session before settling in for the closing price of $6.35. A 52-week range for RXRX has been $5.60 – $12.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 112.62% over the last five years. When this article was written, the company’s average yearly earnings per share was at 2.54%. With a float of $305.79 million, this company’s outstanding shares have now reached $389.55 million.
In terms of profitability, gross margin is 10.66%, operating margin of -814.58%, and the pretax margin is -790.4%.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 23.93%, while institutional ownership is 60.17%. The most recent insider transaction that took place on Mar 05 ’25, was worth 131,600. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $6.58, taking the stock ownership to the 1,256,024 shares. Before that another transaction happened on Mar 06 ’25, when Company’s Chief Executive Officer sold 20,000 for $6.37, making the entire transaction worth $127,400. This insider now owns 1,256,024 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.54% per share during the next fiscal year.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.43 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Analysing the last 5-days average volume posted by the [Recursion Pharmaceuticals Inc, RXRX], we can find that recorded value of 16.14 million was lower than the volume posted last year of 24.83 million. As of the previous 9 days, the stock’s Stochastic %D was 54.82%. Additionally, its Average True Range was 0.75.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 18.34%, which indicates a significant decrease from 37.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.14% in the past 14 days, which was lower than the 99.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.49, while its 200-day Moving Average is $7.29. Now, the first resistance to watch is $7.05. This is followed by the second major resistance level at $7.27. The third major resistance level sits at $7.64. If the price goes on to break the first support level at $6.46, it is likely to go to the next support level at $6.09. Now, if the price goes above the second support level, the third support stands at $5.87.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are 401,991K outstanding shares of the company, which has a market capitalization of 2.75 billion. As of now, sales total 58,840 K while income totals -463,660 K. Its latest quarter income was 4,550 K while its last quarter net income were -178,910 K.
